Novavax, Inc. (NVAX) Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers the unaudited Form 10-Q for the quarterly period ended June 30, 2026. Novavax, Inc. is a biotechnology company focused on vaccine development, utilizing its proprietary Matrix-M® adjuvant and protein-based nanoparticle technology. The company operates as a single reporting segment and is currently executing a strategy centered on strategic partnerships (notably with Sanofi, Pfizer, and Takeda) and capital-efficient R&D. As of June 30, 2026, the company had 164,945,726 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenue | $56,698 | $239,240 | $196,212 | $905,895 |
| Net Income (Loss) | $(53,387) | $106,508 | $(62,878) | $625,154 |
| Diluted EPS | $(0.32) | $0.62 | $(0.38) | $3.55 |
| Operating Cash Flow | N/A | N/A | $(105,230) | $(312,964) |
| Cash & Marketable Securities | $719,340 | N/A | N/A | N/A |
| Long-Term Debt | $291,490 | N/A | N/A | N/A |
Note: Cash and Marketable Securities as of June 30, 2026, totaled $719.3 million ($191.5 million cash + $527.9 million marketable securities). Working capital was $440.5 million.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 76% in Q2 2026 compared to Q2 2025 ($56.7M vs. $239.2M). This was primarily driven by the absence of a $175 million milestone payment from Sanofi recognized in Q2 2025 and the lack of non-recurring revenue from the termination of the Canada and New Zealand Advance Purchase Agreements (APAs) which occurred in 2025.
- Profitability Shift: The company reported a net loss of $53.4 million in Q2 2026, a reversal from the $106.5 million net income in Q2 2025. The loss is attributed to the significant drop in revenue, partially offset by reduced operating expenses.
- Expense Reduction: Total expenses decreased by 19% in Q2 2026 ($111.6M vs. $138.2M). Selling, general, and administrative (SG&A) expenses dropped significantly by 39% ($26.7M vs. $43.6M) due to cost containment measures and a reduced global commercial footprint. R&D expenses decreased by 11% ($70.7M vs. $79.2M).
- Debt Structure: In February 2026, the company entered into a Credit Agreement with MidCap Financial Trust for up to $330 million, funding $50 million at closing. This increased long-term debt balances compared to the prior year.
Guidance, Outlook, and Risks
- Going Concern: Management has evaluated its liquidity and concluded that existing cash, cash equivalents, and marketable securities ($723.9 million total including restricted cash) are sufficient to fund operations for at least the next 12 months.
- Strategic Milestones:
- Sanofi: Manufacturing technology transfer for Nuvaxovid® is expected to complete in mid-2027, triggering a $75 million milestone. Initiation of a Phase 3 trial for the COVID-19/Influenza combination (CIC) vaccine would trigger a $125 million milestone.
- Pfizer: A new license agreement for Matrix-M® adjuvant was signed in January 2026, including a $30 million upfront payment (recognized in Q1 2026) and potential milestones up to $500 million.
- Risks and Contingencies:
- Regulatory Approval: The company is awaiting a final decision on a special access importation application in Australia. Failure to receive regulatory approval for the seasonally updated vaccine by contractual deadlines could result in up to $92.5 million of deferred revenue becoming refundable.
- UK Settlement: The company is paying a $123.8 million refund to the UK government in quarterly installments through June 2027.
- Supply Chain: Significant dependence on Serum Institute of India (SII) for co-formulation and filling of the COVID-19 vaccine.
Investor Verification Checklist
- Australia APA Status: Verify the outcome of the special access importation application with the Therapeutic Goods Administration (TGA) to assess the risk of the $92.5 million potential refund.
- Sanofi Milestone Timing: Monitor progress on the manufacturing technology transfer and the initiation of the CIC Phase 3 trial to confirm the timing of the $200 million in potential near-term milestones.
- Liquidity Runway: Confirm the burn rate against the $723.9 million cash position to validate the 12-month going concern assertion, especially given the net operating cash outflow of $105.2 million in the first half of 2026.
- Debt Covenants: Review compliance with the new Credit Agreement covenants, specifically the requirement to maintain unrestricted cash of at least $100 million.
- UK Refund Payments: Track the quarterly cash outflows related to the $123.8 million settlement with the UK government.